本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Enlivex Therapeutics Ltd.

1.15
+0.110010.58%
盤後1.150.0046+0.40%18:01 EST
成交量:85.59萬
成交額:99.54萬
市值:2.73億
市盈率:-2.13
高:1.25
開:1.03
低:1.03
收:1.04
52周最高:2.10
52周最低:0.6600
股本:2.37億
流通股本:2.35億
量比:4.50
換手率:0.36%
股息:- -
股息率:- -
每股收益(TTM):-0.5394
每股收益(LYR):-0.7319
淨資產收益率:-57.64%
總資產收益率:-36.02%
市淨率:15.62
市盈率(LYR):-1.57

資料載入中...

2025/12/30

SEC問詢函

Form CORRESP - Correspondence
2025/05/09

SEC問詢函

Form CORRESP - Correspondence
2025/05/01

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/11/14

超過5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/04/30

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/04/10

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/05/03

SEC問詢函

CORRESP [Cover] - Correspondence
2022/04/29

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/06/04

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2021/04/30

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/02/10

[補充]招股説明書

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2021/02/09

[補充]招股説明書

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2020/08/14

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/05/18

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/04/30

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/04/13

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/18

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/05

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/02/26

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/02/24

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]